In colorectal cancer, bispecific single-chain fragment variable (scFv) killer engagers (BiKEs) against CD133, which recognize CD133 on CSCs and CD16 on NK cells, were shown to enhance NK cell therapy [299]. The gene discussed is PROM1; the disease is colorectal cancer.